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MAPKp38 MAPK is activated potently during cardiac ischaemia, although the precise mechanism by which it is
activated is unclear. We used the isolated perfused rat heart to investigate the signalling pathways activated
upstream of p38 during global cardiac ischaemia. Ischaemia strongly activated p38α but not the JNK
pathway. The MAPKKs, MKK3, MKK4 and MKK6 have previously been identiﬁed as potential upstream
activators of p38; however, in the ischaemic perfused heart, we saw activation of MKK3 and MKK6 but not
MKK4. MKK3 and MKK6 showed different temporal patterns of activity, indicating distinct modes of
activation and physiological function. Consistent with a lack of JNK activation, we saw no activation of MKK4
or MKK7 at any time point during ischaemia. A lack of MKK4 activation indicates, at least in the ischaemic
heart, that MKK4 is not a physiologically relevant activator of p38. The MAPKKK, ASK1, was strongly
activated late during ischaemia, with a similar time course to that of MKK6 and in ischaemic neonatal cardiac
myocytes ASK1 expression preferentially activated MKK6 rather than MKK3. These observations suggest that
during ischaemia ASK1 is coupled to p38 activation primarily via MKK6. Potent activation of ASK1 during
ischaemia without JNK activation shows that during cardiac ischaemia, ASK1 preferentially activates the p38
pathway. These results demonstrate a speciﬁcity of responses seldom seen in previous studies and illustrate
the beneﬁts of using direct assays in intact tissues responding to physiologically relevant stimuli to unravel
the complexities of MAPK signalling.PK, mitogen-activated protein
kinase; JNK, c-Jun N-terminal
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TAK, TGF β-activated kinase;
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In mammalian cells, mitogen-activated protein kinase (MAPK)
cascades are differentially activated by a wide variety of extracellular
stimuli and contribute to the regulation ofmany cellular responses [1,2].
The extracellularly regulated kinases or ERK family of MAPKs regulate
predominantly the growth and proliferation of cells in response to
factors acting on tyrosine kinase and G-protein-coupled receptors, and
in most cell types, are only weakly activated by stressful stimuli. This is
in contrast to the stress-activated protein kinase or SAPK family of
MAPKs, which includes the c-Jun N-terminal Kinase (JNK) and p38
MAPK. JNKandp38are activated strongly in response to cellular stresses
such as heat and osmotic shock, genotoxic agents, UV irradiation,trophic factor withdrawal and also by pro-inﬂammatory cytokines. JNK
and p38 are also potently activated by ischaemia/reperfusion injury in
the heart where they are thought to contribute to the apoptotic and
hypertrophic responses of cardiac myocytes [3,4]. In the isolated
perfused rat heart, JNK and p38 are differentially activated by ischaemia
and reperfusion [5–7]. p38 is rapidly activated at the onset of ischaemia
and remains active during reperfusion. JNK on the other hand is not
activated by ischaemia alone but is potently activated upon reperfusion,
probably in response to reactiveoxygen species. Although thekinetics of
activation of JNKandp38arewell documented in theperfusedheart, the
mechanism of their activation is poorly characterised. A number of
upstream activators of JNK and p38 have been identiﬁed by cloning and
transfection experiments using cells in culture and mouse gene
knockout experiments. The proposed immediate upstream regulators
of JNK are theMAP kinase kinases MKK4 andMKK7 [8–11], while those
directly activating p38 are MKK3, MKK6 and possibly MKK4 [8,12–15].
Numerous MAP kinase kinase kinases that activate MKKs have been
proposed, and these include the MAPK/ERK kinases (MEKKs), mixed
lineage kinases (MLKs), TGFβ-activated kinase (TAK), germinal centre
kinase (GCK), tumour progression locus-2 (Tpl-2), p21-activated
protein kinases (PAKs), apoptosis-sensitive kinase (ASK1) and thousand
and one (TAO) kinase [2,16,17]. However, the precise arrangement of
these pathways is unclear and since candidate regulators have been
proposed mainly by transfection studies in cultured cell lines, the
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have attempted to address this issue using a physiologically relevant
experimental system. In this study, we have used the isolated perfused
rat heart to investigate the pathways that lead to the activation of p38
during cardiac ischaemia.
2. Materials and methods
2.1. Langendorff perfusion
Terminal anaesthesia was administered to adult male (250–300 g)
Wistar rats by interperitoneal injection of sodium pentobarbitone
(250 mg/kg). After induction of anaesthesia, intravenous heparin
(150 IU) was administered and the heart surgically removed. Hearts
were perfused retrogradely at a pressure of 10 kPa (70 mm Hg) with
Krebs–Henseleit bicarbonate-buffered saline (25 mM NaHCO3,
119 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2 , 1.2 mM KH2 PO4, pH 7.6)
at 37 °C supplementedwith 10 mMglucose and equilibrated with 95%
O2/5% CO2 . The temperature of the hearts and perfusates were
maintained at 37 °C by the use of a water-jacketed apparatus. Hearts
were pre-equilibrated for 15 min prior to induction of ischaemia,
during which time the coronary ﬂow was approximately 10 ml/min.
Simple global ischaemia was induced by interruption of ﬂow for the
times indicated by clamping the aortic perfusion line. Hearts ceased
beating within 1–3 min of ischaemia. As a positive control for kinase
activation, some hearts were perfused with buffer containing 0.5 M
sorbitol for 20 min. Control hearts were perfused for up to 60 min
after the pre-equilibration period without interruption to the
perfusate ﬂow. At the end of all perfusions, hearts were freeze–
clamped between aluminium tongs cooled in liquid N2 and the frozen
tissue stored at −80 °C until required.
2.2. Preparation of neonatal cardiac myocytes
Neonatal cardiac myocytes were isolated from 1- to 3-day-old
Wistar/Sprague–Dawley rat hearts as described previously [18,19].
Brieﬂy, ventricular myocytes were dissociated by digestion at 37 °C
with 0.8 mg/ml collagenase type II (Gibco, #17101-015) and 1.2 mg/
ml pancreatin (Sigma, #P3292) in sterile ADS buffer (116 mM NaCl,
20 mM HEPES, 0.8 mM Na2HPO4, 5.6 mM glucose, 5.4 mM KCl,
0.8 mM MgSO4, pH 7.35). The cells were resuspended in mainte-
nance medium; Dulbecco's modiﬁed Eagle's medium/medium 199
(4:1 (v/v)), containing 100 U/ml of both penicillin and streptomycin,
supplementedwith 10% horse serum and 5% foetal calf serum (Gibco),
prior to preplating on uncoated culture dishes for 60 min at 37 °C to
deplete ﬁbroblasts. The non-adherent myocytes were plated at a ﬁnal
density of 1×106 cells/dish in 4 ml maintenance medium on 60-mm
dishes coated with gelatin. The culture medium was exchanged for
fresh maintenance medium after overnight incubation.
2.3. Cell treatments and preparation of lysates
Neonatal cardiac myocytes, plated onto 60-mm collagen-coated
dishes and incubated overnight in maintenance medium containing
2% foetal calf serum, were washed once with PBS at 37 °C prior to
incubation for the indicated times with control buffer (4 mM HEPES,
pH 7.5, 137 mM NaCl, 3.58 mM KCl, 0.49 mM MgCl2, 0.9 mM MgCl2,
5.59 mM D-glucose, 2% FCS) or ischaemia buffer (4 mMHEPES, pH 6.5,
137 mMNaCl, 16 mMKCl, 0.49 mMMgCl2, 0.9 mMMgCl2, 5.59 mM D-
glucose, 2% FCS, 10 mM2-deoxyglucose, 20 mM sodium lactate, 1 mM
sodium dithionite). As a positive control and to allow the measure-
ment of maximal kinase activation, some cells were osmotically
shocked by incubation with control buffer containing 0.5 M sorbitol.
After the treatments indicated, cells were washed once with ice-cold
PBS and lysed by scraping into 0.5 ml of ice-cold Triton lysis buffer
(20 mM HEPES, pH 7.5, 137 mM NaCl, 25 mM β-glycerol phosphate,2 mM sodium pyrophosphate, 2 mM EDTA, 10% glycerol, 1% Triton X-
100, 1 mM PMSF, 2.5 μg/ml each of pepstatin, antipain and leupeptin,
2 mM benzamidine, 0.5 mM DTT, 1 mM Na3VO4). Lysates were
vortexed and clariﬁed by centrifugation at 20,000×g for 15 min at
4 °C. Heart extracts were prepared from frozen perfused hearts which
were pulverised under liquid N2 in a pre-cooled pestle and mortar.
Approximately 200 μg of the powdered heart tissue was extracted
into 900 μl of ice-cold lysis buffer (20 mM HEPES, pH 7.5, 137 mM
NaCl, 25 mM β-glycerol phosphate, 2 mM sodium pyrophosphate,
2 mM EDTA, 10% glycerol, 1 mM PMSF, 2.5 μg/ml each of pepstatin,
antipain and leupeptin, 2 mM benzamidine, 0.5 mM DTT, 1 mM
Na3VO4) using a PowerGen 35 tissue homogeniser set at full power
(Fisher Scientiﬁc). Lysates were clariﬁed by centrifugation at
20,000×g for 15 min at 4 °C.
2.4. RT-PCR analysis
Total RNA was extracted from approximately 100 mg rat heart
tissue or neonatal cardiac myocytes using RNAwiz reagent (Ambion).
cDNA was generated from 1 μg of total RNA in a reverse transcription
reaction containing 10 mM Tris–HCl, pH 9.0, 5 mMMgCl2, 50 mMKCl,
0.1% Triton X-100, 1 mM dNTPs, 1 U/μl RNasin RNase inhibitor, 0.5 μg
oligo (dT)15 primers and 16 U AMV reverse transcriptase (Promega).
Reverse transcription was carried out for 1 hour at 42 °C. cDNA gen-
erated by reverse transcription was used as template in polymerase
chain reactions to amplify p38 isoforms using speciﬁc primers. Their
sequences were: p38α forward 5′-AAG AAA ATC TCC TCA GAG TCT-3′,
reverse 5′-AAT GAC TTC ATC GTA GGT CAG-3′; p38β forward 5′-TCC
TCG GAG CAT GCC CGG ACA-3′, reverse 5′-CAG GGA GCT GTG AGG
GTT CCA-3′; p38γ forward 5′TGC TTC TGT CCT GAC CAA TGC-3′,
reverse 5′-ACT CTG GCT CCT AGC TGC CTG-3′; p38δ forward 5′-CAC
ACA GCT TTT CCC ACG CGC-3′, reverse 5′-CCT CGA GTC CTT CCG GGC
TAT-3′. PCR products were separated by electrophoresis on a 1%
agarose gels and their identity conﬁrmed by DNA sequencing
(Applied Biosystems).
2.5. Immunoprecipitation and kinase assays
Clariﬁed lysates from neonatal cardiac myocytes or perfused
hearts (500–700 μg total protein) were incubated with 5 mg Protein-
A Sepharose and 5 μl of antiserum to either Flag, JNK, p38, MKK3,
MKK6, MKK4, MKK7 or ASK1 in lysis buffer, adjusted to a ﬁnal volume
of 500 μl and mixed by tumbling at 4 °C. After 3 hours, immune
complexes were isolated by a brief low-speed spin at 4 °C and
precipitates washed three times with 1 ml of ice-cold lysis buffer.
Precipitates were then either resuspended in SDS–PAGE sample buffer
prior to western blotting analysis or washed once more with 1 ml of
kinase assay buffer (25 mM HEPES, pH 7.4, 25 mM β-glycerol
phosphate, 25 mM MgCl2, 0.5 mM Na3VO4, 0.5 mM DTT) prior to
kinase assay. For kinase assays, immunoprecipitates were resus-
pended in kinase assay buffer to a ﬁnal volume of 50 μl containing
50 μM [γ-32P] ATP (2000 cpm/pmol) and the relevant protein
substrates required for each kinase, which were; 5 μg of GST-ATF2
(1-109) for p38, 5 μg of GST-c-Jun (1-79) for JNK, 1 μg GST-p38
and 4 μg GST-ATF2 for MKK3 and MKK6, 1 μg GST-JNK and 4 μg of
GST-c-Jun (1-79) for MKK4 and MKK7 or 5 μg of myelin basic protein
for ASK1. All kinase assays were terminated, after incubation for
30 min at 30 °C, by the addition of SDS–PAGE sample buffer. The
samples were then subjected to electrophoresis on 10% SDS–PAGE
gels.
32
P-incorporation into protein substrates was determined by
PhosphorImager analysis of the dried gels (Molecular Dynamics).
2.6. Cell culture
HEK-293 human embryonic kidney cells were cultured in
Dulbecco's modiﬁed Eagle's medium (Gibco) supplemented with
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and 100 μg/ml streptomycin. Cells were maintained at 37 °C in a
humidiﬁed atmosphere containing 5% CO2.
2.7. Transfection of neonatal cardiac myocytes
Rat neonatal cardiac myocytes, plated at 1×106 cells/dish on 60-
mm collagen-coated dishes, were transfected 48 hours after isolation.
Plasmid cDNA constructs (1 μg) were transfected using Fugene-6
according to the manufacturer's instructions. Myocytes were cultured
for a further 48 hours, replacing medium after 24 hours, before
treatment and lysis. For adenoviral transfection, neonatal cardiac
myocytes were infected with adenovirus pAdEasy1-WT-ASK1
(expressing GFP and WT-ASK1 under separate CMV promoters) at
an MOI of 50 using a viral stock of titre 109–1010 viral particles/ml.
GFP ﬂuorescence indicated ∼50% efﬁciency of infection after 24 hours.
Cells were used for experiments 48 h post-infection.
2.8. Western blotting
Immunoprecipitates or cell lysates (200 μg total protein) were
subjected to SDS–PAGE on 8% or 10% polyacrylamide gels [20].
Proteins were transferred to Immobilon-P membranes (Millipore)
using semi-dry electrophoretic transfer (Biorad) and the membranes
blocked for 1 hour in 3% (w/v) bovine serum albumin (BSA) in TBST
(10 mM Tris–HCl, pH 7.5, 150 mMNaCl, 0.02% (v/v) Tween-20). Blots
were incubated for 1 hour with primary antibody diluted in TBST
containing 3% (w/v) BSA. The blots were then washed three times for
15 min in TBST prior to incubation in the appropriate horseradish
peroxidase-coupled secondary antibody (GE Healthcare) at 1:10,000
dilution in TBST with 3% (w/v) BSA. Blots were again washed three
times in TBST before being developed using enhanced chemilumi-
nescence (GE Healthcare) and exposure to X-ray ﬁlm (Fuji).
2.9. GST-fusion proteins
GST fusions of JNK, p38, c-Jun (1-79) and ATF2 (1-109) were
expressed in E. coli using pGEX vectors and puriﬁed by glutathione
agarose afﬁnity chromatography as described previously [21].
2.10. Antibodies
Anti-JNK antibody (Cat. no. 554 285) was from BD Biosciences. A
rabbit polyclonal antibody to p38 was generated against a GST fusion
of full-length p38 [21]. The phosphorylation site-speciﬁc antibodies
anti-phospho-p38 (Cat. no. 9211), anti-phospho-JNK (Cat. no. 9251)
and anti-phospho-Thr 845 ASK1 (Cat. no. 3765) were from Cell
Signalling Technology. Antibodies to MAPK kinases were from Santa
Cruz Biotechnology: MKK3 (Cat. no. sc-960), MKK6 (Cat. no. sc-1991),
MKK4 (Cat. no. sc-964) and MKK7 (Cat. no. sc-7103). Anti-GFP (Cat.
no. G6539), anti-FlagM2 (Cat. no. F-3165) and anti-γ-tubulin (Cat. no.
T6557) were from Sigma. Anti-ASK1 rabbit polyclonal antiserum was
the kind gift of Prof. Hidenori Ichijo, University of Tokyo. Anti-mouse
and anti-rabbit horseradish peroxidase-conjugated secondary anti-
bodies were from GE Healthcare, UK.
2.11. Constructs
Vectors expressing Flag-tagged MKK3, MKK6, MKK4 and MKK7
have been described previously [22] as have pGEX vectors for
expressing GST fusions of JNK, p38, c-Jun and ATF2 [21]. Constructs
expressing Flag-tagged p38 isoforms (p38α, β, γ and δ) were obtained
from Dr. Raj Patel, University of Leicester. pcDNA3-HA-ASK1 was the
kind gift of Prof. Hidenori Ichijo, University of Tokyo. Adenoviral
vectors expressing full-length, wild-type, HA-tagged ASK1 were
constructed by subcloning the ASK1 cDNA into the pAdEasy transfervector prior to homologous recombination in E. coli into the pAdEasy-
1 viral backbone (Stratagene). pAdEasy-1-WT-ASK1 vector was
puriﬁed from E. coli, linearised and used to infect HEK-293A cells to
produce packaged recombinant adenovirus. High-titre adenoviral
stocks were generated by sequential passage in HEK-293A cells
according to the manufacturer's instructions (Stratagene).
3. Results
3.1. SAPK activation during cardiac ischaemia
To conﬁrm which SAPKs are activated during cardiac ischaemia,
perfused rat hearts were subjected to global ischaemia and extracts
assayed for p38 and JNK activity by immune-complex kinase assay.
As expected, we saw a large and rapid increase in p38 kinase
activity in response to ischaemia, which appeared to be bi-phasic,
with little or no JNK activation (Fig. 1A and B). To determine which
p38 isoforms are expressed and might be activated by ischaemia in
the heart, we performed RT-PCR analysis. We were able to detect a
strong signal for p38α, with weaker signals for the β and γ isoforms
(Fig. 1C, upper panel). We were unable to detect the p38δ transcript
in heart extracts even though a control p38δ cDNA gave a strong RT-
PCR signal (Fig. 1C, lower panel). To determine which p38 isoforms
our polyclonal p38 antiserum was capable of precipitating, we
immunoprecipitated Flag-tagged p38 from HEK cells transfected
with the various p38 isoforms. Western blotting with anti-Flag
showed that the p38 antibody was able to precipitate each of the
p38 isoforms equally well (Fig. 1D). These results suggest that in the
perfused heart p38α is the major contributor to increased p38
activity during ischaemia.
To further investigate the contribution of the various p38 isoforms
to SAPK activity during ischaemia, we investigated p38 activation in
neonatal cardiac myocytes subjected to simulated ischaemia. Similar
to the experiments in the perfused heart, we saw robust activation of
p38 during ischaemia with little or no activation of JNK (Fig. 1A). p38
isoform expression in neonatal cardiacmyocytes was similar to that in
the adult heart, RT-PCR analysis revealing the expression of p38α, β
and γ but not δ, although the expression of p38γ seemed to be higher
in the neonatal myocytes (Fig. 2B). To determine which p38 isoforms
could be activated by ischaemia, we transfected neonatal myocytes
with Flag-tagged p38 isoforms and subjected them to ischaemia for
20 min prior to immunoprecipitation with anti-Flag antibody and
immune-complex kinase assay. Both p38α and p38δ were strongly
activated by ischaemia while p38β and p38γ remained unaffected
(Fig. 2C). In a control experiment, osmotic shock strongly activated all
of the transfected p38 isoforms showing that all were efﬁciently
expressed and capable of activation (Fig. 2D). Taken together, these
experiments suggest that p38α is the SAPK most signiﬁcantly
activated during cardiac ischaemia.
3.2. MAPKK activation during cardiac ischaemia
To investigate further the pathway of SAPK activation during
ischaemia, we assayed the kinases thought to lie upstream of p38 and
JNK. Perfused hearts were subjected to ischaemia and extracts assayed
for MKK activity using immune-complex kinase assays. Both of the
known p38 activators MKK3 and MKK6 were activated by ischaemia
but with different time courses (Fig. 3A and B). MKK3 appeared to
have a relatively high basal activity but was activated further by
ischaemia and remained active throughout the time course (Fig. 3A).
MKK6 was also activated signiﬁcantly by ischaemia but not until later,
with the ﬁrst detectable increase at 30 min and remaining active until
the end of the time course (Fig. 3B). In contrast, neither of the JNK
activators MKK4 or MKK7 showed a signiﬁcant increase in activity
during ischaemia in the perfused heart (Fig. 3C and D). In control
experiments in which hearts were perfused with sorbitol, we saw
Fig. 1. Time course of SAPK activation during cardiac ischaemia. Freshly isolated perfused rat hearts were subjected to global ischaemia for the times indicated, extracted and assayed
for p38 (A) or JNK (B) activity by immune-complex kinase assay. The range of p38 isoforms expressed in the normal adult rat heart was determined by RT-PCR analysis with isoform-
speciﬁc primers using tissue from unstimulated hearts (C; upper panel). cDNAs for p38α, β, γ and δwere used as positive controls (lower panel). The isoform speciﬁcity of the p38
antibody used in immune-complex kinase assays was determined by immunoprecipitation from cell lysates containing epitope-tagged forms of p38α, β, γ and δ, followed by SDS–
PAGE and western blotting with anti-Flag antibody (D).
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MKKs were present and could be activated by osmotic shock (Fig. 3E).
No MKK activity was detected in immunoprecipitates using control
antibody, or in assays lacking GST-MAPK or substrate (Fig. 3E).Fig. 2.Differential activation of SAPK isoforms during simulated ischaemia. Primary neonatal
lysates examined by SDS–PAGE and western blotting with anti-phospho p38 and anti-ph
treatment with 0.5 M sorbitol for 20 min (A). The range of p38 isoforms expressed in unstim
speciﬁc primers (B; top panel). cDNAs for p38α, β, γ and δwere used as positive controls (lo
isoforms α, β, γ and δ. The cells were subjected to simulated ischaemia for 20 min (C) or tre
the cell extracts using anti-Flag antibody and assayed in an immune-complex kinase assayAntibody speciﬁcity was demonstrated by speciﬁc immunoprecipita-
tion of Flag-tagged MKKs (Fig. 3F).
These data are entirely consistent with activation of p38 but not
JNK and rule out a role for MKK4 in the activation of p38 duringcardiac myocytes were subjected to simulated ischaemia for the times indicated and cell
ospho JNK antibodies. As a positive control, cells were osmotically shocked (OS) by
ulated neonatal cardiac myocytes was determined by RT-PCR analysis using isoform-
wer panel). Primary neonatal cardiac myocytes were transfected with Flag-tagged p38
ated with 0.5 M sorbitol for 20 min (D). Transfected p38 was immunoprecipitated from
.
Fig. 3. Differential activation of SAPK activators during cardiac ischaemia in perfused hearts. Freshly isolated perfused rat hearts were subjected to global ischaemia for the times
indicated, extracted and assayed for MKK3 (A), MKK6 (B), MKK4 (C) and MKK7 (D) activity by coupled immune-complex kinase assay. Extracts prepared from hearts perfused
without (Con) or with 0.5 M sorbitol were used in control MKK assays lacking either GST-p38/JNK (no MAPK), GST-ATF2/Jun (no substrate) or immunoprecipitated with control
antiserum (E). Extracts of HEK 293 cells, transfected with Flag-tagged MKKs, were immunoprecipitated with either control serum or antisera speciﬁc for the various MKKs assayed.
Immunoprecipitated MKKs were detected by western blotting with anti-Flag antibody (F).
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myocytes subjected to simulated ischaemia with activation of MKK3
and MKK6 and poor activation of MKK4 and MKK7 (Fig. 4A).
3.3. ASK1 activation during cardiac ischaemia
To test if the MAPKKK ASK1 were activated by ischaemia, we
immunoprecipitated ASK1 from ischaemic and control hearts and
assayed its activity in an immune-complex kinase assay. There was a
gradual but strong activation of ASK1 during ischaemia peaking at
45 min (Fig. 5A) similar to that seen for MKK6 (Fig. 3B). At later time
points ASK1 activity declined, similarly to that seen for p38 (Fig. 1A).
To investigate the coupling of ASK1 to downstream pathways, we
subjected neonatal cardiac myocytes expressing ASK1 to simulated
ischaemia and measured the activity of the kinases thought to lie
downstream. Cells were transfected with ASK1 to ensure robust
activation of downstream pathways and to compare the coupling in
both stimulated and unstimulated cells.Similarly to the perfused heart experiments, we saw a strong
activation of ASK1 during ischaemia which correlated with increased
p38 activity (Fig. 5B). To determine which downstream kinases ASK1
was likely to couple to, we compared MKK3 and MKK6 activation by
ischaemia in cells transfected with or without ASK1. In untransfected
cells, we saw activation of both MKK3 and MKK6 by ischaemia as
expected. However, in cells transfected with ASK1, we saw enhanced
activation of both MKK3 andMKK6with the activation of MKK6 being
most affected, particularly in unstimulated cells (Fig. 5C). Taken
together with the co-incident activation of MKK6 and ASK1 during
ischaemia, these data suggest that activation of ASK1 leads to
preferential activation of MKK6 and consequent activation of p38.
4. Discussion
Genetic and biochemical studies have allowed the rapid delinea-
tion of the multiple MAPK signalling pathways found in all eukary-
otes and the involvement of MAPKs themselves in many important
Fig. 5. Activation ASK1 and downstream MKKs during cardiac ischaemia. Perfused rat
hearts were subjected to global ischaemia for the times indicated, extracted and
assayed for ASK1 activity by immune-complex kinase assay (A). Heart extracts were
immunoprecipitated with control serum or anti-ASK1 antibody and precipitated ASK1
detected by western blotting with anti-ASK1 antibody (inset). Primary neonatal cardiac
myocytes, infected with an adenoviral vector expressing wild-type ASK1, were
subjected to simulated ischaemia or maintained in control buffer for the times
indicated. Cell extracts were prepared, separated by SDS–PAGE and blotted with anti-
phospho-ASK1 and anti-phospho-p38 antibody. Equal infection rates and gel loading
were conﬁrmed by blotting with anti-GFP and anti-γ-tubulin, respectively (B). Primary
neonatal cardiac myocytes, infected with an adenoviral vector expressing wild-type
ASK1 (ASK1) or empty vector (Con), were subjected to simulated ischaemia (black
bars) or maintained in normal buffer (open bars) for 15 min. Lysates were prepared and
MKK3 and MKK6 activity measured using coupled immune-complex kinase assays.
Kinase activity is expressed relative to the empty vector control in unstimulated cells
(C). Proposed routes for p38 activation by MKKs during ischaemia (D).
Fig. 4. Differential activation of SAPK activators by simulated ischaemia in neonatal
cardiac myocytes. Primary neonatal cardiac myocytes were subjected to simulated
ischaemia or maintained in control buffer for the times indicated and cell extracts
assayed for MKK activity by coupled immune-complex kinase assay. As a positive
control, extracts from cells treated with 0.5 M sorbitol for 30 min (OS) were also
assayed for each MKK.
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of many of the upstream components in these pathways is uncertain
since relatively few of them have been assayed directly after phys-
iologically relevant stimulation in intact tissues. SAPKs are strongly
activated by ischaemia/reperfusion in the heart and play an important
role in cardiac function, although the exact mechanism of activation is
poorly understood [3,4]. To address this, we set out to assay directly
the upstream activators of SAPKs during ischaemia in the perfused rat
heart. This an ideal experimental system with which to investigate
the activators upstream of p38 independently of JNK, since most
investigators report p38 but not JNK activation during ischaemia, with
both activated on reperfusion [5–7]. This is in contrast with many
other stimuli which often activate both p38 and JNK together [1,2].
4.1. p38 activation during ischaemia
In agreement with earlier reports, we found good activation of p38
during ischaemia without signiﬁcant JNK activation in the perfused
rat heart (Fig. 1A and B). This was conﬁrmed in neonatal cardiac
myocytes exposed to themetabolic stresses associatedwith ischaemia
(Fig. 1E).
A lack of good, precipitating, isoform-speciﬁc p38 antibodies
makes it difﬁcult to determine exactly which isoforms are activated by
ischaemia in the perfused heart by direct assay. By RT-PCR analysis,
we found that the p38α transcript was readily detected in both adult
heart and neonatal cardiac myocytes (Figs. 1C and 2C). This is in
agreement with studies in other species and the consensus seems
to be that the predominant p38 isoform expressed in the heart is α
[23–26]. However, we also found evidence for a low level of ex-
pression of p38β, as have others [24,26], although some earlier studies
concluded that p38β was absent [23,25,27]. Together these observa-
tions suggest that p38β is clearly less abundant in the heart than theα
isoform. In agreement with previous studies in the rat, mouse and in
humans [28], we also detected the p38γ transcript in the adult rat
tissue, although at low levels. The p38γ transcript was detected at a
higher level in neonatal myocytes, possibly reﬂecting a role in cardiac
myocyte differentiation [29]. In contrast to studies in humans and
mouse [24,25], we were unable to detect the p38δ transcript in either
adult heart or neonatal rat cardiomyocytes. This would seem to rule
out a role for p38δ in cardiac ischaemia/reperfusion injury, at least in
the rat.
In neonatal cardiac myocytes transfected with Flag-tagged p38
isoforms, we saw signiﬁcant activation of p38α and p38δ but not β or
γ, even though they were all strongly activated by osmotic shock
(Fig. 2B). Since the antibody used in our p38 immune-complex kinase
assays recognises all of the four p38 isoforms equally (Fig. 1D) andgiven the levels of expression of the p38 isoforms in the heart and
their differential activation by the stresses associated with ischaemia,
our observations suggest that it is the α isoform contributing most to
the p38 activity we can measure in heart extracts and therefore the
p38 isoform most relevant to cardiac ischaemia in vivo.
4.2. Activation of MKK isoforms
It is clear from genetic and biochemical studies that the immediate
upstream activators of JNK are MKK4 [8,9] and MKK7 [10,11] while
p38 seems to be activated by MKK3 [8] and MKK6 [12,13], although
739S.J. Harding et al. / Biochimica et Biophysica Acta 1802 (2010) 733–740some studies have also suggested a role for MKK4 [8,14,15]. However,
as far as we are aware, the direct upstream activators of JNK and p38
have not been assayed directly in the perfused heart. Consistent with
robust p38 activation during ischaemia, we saw strong activation of
both MKK3 and MKK6. There was no signiﬁcant activation of either
MKK4 or MKK7 during ischaemia, which is consistent with the lack of
JNK activation. The absence of MKK4 activation is signiﬁcant since
previous reports have shown that MKK4 may activate p38 [8,14],
although the exact route to p38 activationmay be stimulus dependent
[15]. In our study, the lack of MKK4 activation under conditions where
p38 is strongly activated clearly rules out a role for MKK4 in the
activation of p38 during cardiac ischaemia.
Interestingly, we observed different kinetics of activation for
MKK3 and MKK6 during ischaemia, with MKK3 being activated
rapidly and remaining active, while MKK6 was not activated sig-
niﬁcantly until later in the time course. This clearly suggests that there
are different pathways operating upstream of MKK3 andMKK6which
are active at different times during ischaemia. It also suggests dif-
ferent physiological functions for MKK3 and MKK6, which is in
accordance with previous studies showing differences apparent in T-
cell apoptosis [30], cardiac stress responses [31] and remodelling [23].
These effects may be linked to the ability of MKK3 and MKK6 to
activate different p38 isoforms [32–34].
4.3. Activation of ASK1 by ischaemia
MAPKKs are themselves activated by a diverse array of MAPKKKs
that link extracellular signals to downstream MAPK signalling path-
ways [16,17]. We found the assay of MAPKKKs in heart extracts to be
rather problematic, probably due to a combination of relatively low
abundance of the kinases themselves and/or the poor quality of some
the MAPKKK antisera available to us. However, we had good reagents
for ASK1, a redox-sensitive MAPKKK that has been shown to activate
the p38 and JNK pathways and which is thought to be involved in
the response to many cellular stresses [35,36]. ASK1 assays were
straightforward and we found ASK1 to be strongly activated by
ischaemia in the perfused rat heart, with a gradual increase in activity
during ischaemia, reaching maximal activation at 45 min (Fig. 5A).
This is in agreement with other studies showing activation of ASK1 by
ischaemia in the brain, spinal cord, kidney, heart and in a mouse
model of ischaemia-induced angiogenesis [37–42].
4.4. Coupling of ASK1 to downstream pathways
Since both p38 and MKK3 were activated strongly at the onset of
ischaemia, before signiﬁcant ASK1 activation, it is unlikely that ASK1
plays a role in activation of p38 via MKK3 at early time points,
implying that a different MAPKKK is responsible (Fig. 5D). Further
work will be required to determine which other MAPKKKs are active
early in ischaemia [16,17]. The time course of ASK1 activation more
closelymatched that ofMKK6 thanMKK3, suggesting that ASK1might
be coupled to MKK6 during ischaemia. This idea is further reinforced
by the observation that expression of ASK1 alone in unstimulated
neonatal cardiac myocytes activated both MKK3 and MKK6 but with a
much larger fold effect on MKK6. MKK6 activation in ischaemic cells
was also increased by expression of ASK1 but the fold effect ap-
peared lower than that for MKK3 due to the higher basal MKK6
activity (Fig. 5C). ASK1 activation occurring late during ischaemia also
correlates well with the phenotype of ASK1(−/−) MEF cells, where
only the late, sustained activation of p38 required for apoptosis by
TNFα is abolished by the knockout of ASK1 [43].
These observations show that there are different pathways active
during early vs. late ischaemia. Activation of p38 in early ischaemia
probably occurs via an unidentiﬁed MAPKKK and MKK3 without
involvement of ASK1 or MKK6. Later, ASK1 contributes to p38activation, most likely via MKK6, although MKK3 may also be
involved (Fig.D).4.5. MKK-independent pathways of p38 activation
Recent work has suggested that there may be MKK-independent
pathways to p38 activation during cardiac ischaemia that involve
TAB1-mediated autophosphorylation of p38, perhaps in conjunction
with the AMP-activated protein kinase (AMPK) [44–47]. Although we
see activation of both MKK3 and MKK6 in the perfused rat heart,
which should be sufﬁcient for full activation of p38, we cannot rule
out the possibility that an MKK-independent component, such as
TAB1 or AMPK, may contribute to p38 activation during ischaemia.
However, full activation of p38 requires dual phosphorylation of the
TGY motif in the kinase domain, and this requires an MKK since p38
poorly autophosphorylates the tyrosine in this motif. In addition,
MKK3/MKK6 compound knockouts seem to abolish p38 activation
completely in MEFs, at least for TNFα [15]. Recent work also suggests
that although AMPK is activated by cardiac ischaemia, it may not be
involved in p38 activation [48]. Clearly further work will be required
to clarify the role ofMKK-independentmodes of p38 activation during
ischaemia in vivo.4.6. ASK1 coupling to the JNK pathway
It is clear that ASK1 can contribute to activation of the JNK
pathway by cell stresses and cytokines [43]. However, during cardiac
ischaemia, we observed strong stimulation of ASK1 activity in the
absence of JNK activation, suggesting that, at least in this context,
ASK1 does not appear to be an activator of the JNK pathway. This is
consistent with the results of a study of ASK1(−/−) mice which
showed a clear attenuation of p38 activation during cardiac
ischaemia in the knockout [42]. However, there was also no JNK
activation in the wild-type during ischaemia, when ASK1 was clearly
active, and only a small reduction of JNK activity upon reperfusion in
the ASK1 knockout. Taken together, these results suggest that
during cardiac ischaemia ASK1 couples preferentially to p38 rather
than JNK.4.7. Role of the ASK1/p38 pathway in cardiac responses to ischaemia
The involvement of ASK1 and p38 pathways in coordinating tissue
responses to cellular stresses including ischaemia/reperfusion injury
is clear and has been documented extensively [3,4,36,42,49,50].
The general consensus appears to be that p38 activation during
ischaemia is likely to be detrimental and contributes to tissue injury
since inhibition of p38 with the pyridinyl imidazole SB203580, and
related compounds, seems to be protective [50]. The interpretation of
this is complicated by the fact that these compounds inhibit p38α and
β but not γ or δ. However, our data and those of others suggest that in
the perfused heart p38γ and δmay not play a major role in ischaemic
injury.
The different p38 isoforms appear to have different functions, with
p38α having been linked to apoptosis and p38β promoting survival
and hypertrophy [31,50–53]. p38α(−/−) mice do not survive [54] but
those expressing a dominant-negative p38α appear to be protected
from cardiac ischaemia/reperfusion injury, thus reinforcing the
notion that p38α activation is detrimental [55].
The regulation of the p38 pathway in the ischaemic heart is clearly
complex. A fuller understanding of the role of p38 in cardiac ischaemia
will require further work with better isoform-speciﬁc p38 inhibitors
combined with a careful analysis of cardiac-speciﬁc knockouts of the
various p38 isoforms.
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